# Conexeu Sciences Raises $5M for FDA Submission

> Conexeu Sciences closes $5M private placement to fund FDA 510(k) submission by Q1 2027.
- Title: Conexeu Sciences Raises $5M for FDA Submission · Financialpost
- Summary: Conexeu Sciences closes $5M private placement to fund FDA 510(k) submission by Q1 2027. Conexeu Sciences raised $5 million through private placement to…
- Keywords: conexeu sciences, nasa, nasdaq, cnxu, fda 510k, wound care device, private placement, regulatory testing, preclinical work, seahawks, seattle, money
- Source: Financialpost — https://financialpost.com/globe-newswire/conexeu-sciences-announces-5-million-private-placement-led-by-existing-shareholders-management-and-directors
- Read time: 1 min
- Topics: conexeu sciences, nasa, nasdaq, cnxu, fda 510k, wound care device, private placement, regulatory testing, preclinical work, seahawks, seattle, money
## Conexeu Sciences Announces $5M Private Placement
Conexeu Sciences Inc. closed a private placement of approximately $5 million led by existing shareholders, management, and directors.
## Escrowed Funds for Stockholder Approval
The $250,000 from management and directors is held in escrow pending stockholder approval under Nasdaq Listing Rule 5635(c).
## Private Placement Terms
The Private Placement consists of 1,666,667 units at $3.00 per unit, each unit includes one share and one warrant to purchase one share at $3.00.
## Special Warrants for Canadian Subscribers
For Canadian subscribers, the Company issued special warrants at $3.00 each, convertible into one share and one warrant upon British Columbia Securities Commission approval or February 16, 2027.
## Leadership Team
The Private Placement was led by CEO Miles Harrison and Chief Commercial Officer David Bogart.
## Funding Purpose
Conexeu plans to use net proceeds for manufacturing scale-up, regulatory testing, and preclinical work toward FDA 510(k) submission by Q1 2027.
## Recent Progress
The financing follows Conexeu's Oct. 6, 2026 program update showing scaled-up CXU material met specifications and on track for Q1 2027 FDA submission.
## Key takeaway

Conexeu Sciences raised $5 million through private placement to support FDA 510(k) submission for its wound care device candidate by Q1 2027.